U.S. Markets closed

Heat Biologics, Inc. (HTBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.89-0.20 (-2.82%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.09
Open6.96
Bid6.95 x 900
Ask7.00 x 1000
Day's Range6.80 - 7.14
52 Week Range1.40 - 30.10
Volume803,839
Avg. Volume1,356,664
Market Cap157.328M
Beta (5Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-1.99
Earnings DateAug 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.25
  • ACCESSWIRE

    Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

    DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B.

  • ACCESSWIRE

    Heat Biologics Commences Manufacturing Process for ZVX-60

    DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc.Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials.

  • ACCESSWIRE

    Heat Biologics Promotes William L. Ostrander to Chief Financial Officer

    DURHAM, NC / ACCESSWIRE / January 11, 2021 /Heat Biologics, Inc. ("Heat")(NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021.